• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型心肌病患者植入起搏器后全因死亡率的超声心动图预测因素

Echocardiographic Predictors of All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy following Pacemaker Implantation.

作者信息

Zhang Nixiao, Hua Wei, Li Xiaoping, Hu Yiran, Niu Hongxia, Cai Chi, Gu Min, Chen Xuhua, Zhang Shu

机构信息

Cardiac Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.

Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu 610072, China.

出版信息

Cardiol Res Pract. 2020 Feb 14;2020:2923767. doi: 10.1155/2020/2923767. eCollection 2020.

DOI:10.1155/2020/2923767
PMID:32148950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7042507/
Abstract

OBJECTIVES

To examine the association between the echocardiographic parameters measured as left atrial diameter (LAD) and left ventricular end-diastolic diameter (LVEDD) and long-term risk of all-cause mortality in adults with hypertrophic cardiomyopathy (HCM) following pacemaker implantation.

METHODS

A total of 94 adult patients with HCM who underwent pacemaker implantation from November 2002 to June 2013 in our Arrhythmia Center for symptomatic bradycardia and did not receive an implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy (CRT) during follow-up were retrospectively extracted.

RESULTS

After careful examination of the medical records, we retrospectively evaluated the clinical characteristics of 74 patients with LAD records (58.1 ± 14.9 years) and 76 patients with LVEDD records (57.6 ± 15.2 years). Based on the receiver-operating characteristic (ROC) curve, the values of LAD = 44 mm and LVEDD = 43 mm were identified to predict the all-cause mortality. In the Kaplan–Meier survival, LAD ≥44 mm and LVEDD ≥43 mm were both significantly associated with all-cause mortality (log-rank test P < 0.05). Cox regression analysis indicated that LAD ≥44 mm (HR 3.580; 95% CI = 1.055–12.148; P=0.041) was an independent predictor of all-cause mortality, while LVEDD ≥43 mm was not significantly associated with all-cause mortality. LVOTO was also significantly associated with all-cause mortality (HR = 0.166; 95% CI = 0.036–0.771; P=0.022).

CONCLUSIONS

In HCM patients with pacemaker implantation, LAD ≥44 mm was an independent predictor of all-cause mortality.

摘要

目的

探讨肥厚型心肌病(HCM)成人患者起搏器植入后,以左心房直径(LAD)和左心室舒张末期直径(LVEDD)测量的超声心动图参数与全因死亡长期风险之间的关联。

方法

回顾性提取2002年11月至2013年6月在我院心律失常中心因症状性心动过缓接受起搏器植入且随访期间未接受植入式心脏除颤器(ICD)或心脏再同步治疗(CRT)的94例成年HCM患者。

结果

仔细查阅病历后,我们回顾性评估了74例有LAD记录患者(58.1±14.9岁)和76例有LVEDD记录患者(57.6±15.2岁)的临床特征。根据受试者工作特征(ROC)曲线,确定LAD = 44 mm和LVEDD = 43 mm的值可预测全因死亡。在Kaplan-Meier生存分析中,LAD≥44 mm和LVEDD≥43 mm均与全因死亡显著相关(对数秩检验P < 0.05)。Cox回归分析表明,LAD≥44 mm(HR 3.580;95%CI = 1.055 - 12.148;P = 0.041)是全因死亡的独立预测因素,而LVEDD≥43 mm与全因死亡无显著关联。左心室流出道梗阻(LVOTO)也与全因死亡显著相关(HR = 0.166;95%CI = 0.036 - 0.771;P = 0.022)。

结论

在植入起搏器的HCM患者中,LAD≥

相似文献

1
Echocardiographic Predictors of All-Cause Mortality in Patients with Hypertrophic Cardiomyopathy following Pacemaker Implantation.肥厚型心肌病患者植入起搏器后全因死亡率的超声心动图预测因素
Cardiol Res Pract. 2020 Feb 14;2020:2923767. doi: 10.1155/2020/2923767. eCollection 2020.
2
Left ventricular dimensions predict risk of appropriate shocks but not mortality in cardiac resynchronization therapy-defibrillator recipients with left bundle-branch block and non-ischemic cardiomyopathy.左心室维度可预测左束支传导阻滞和非缺血性心肌病的心脏再同步治疗除颤器患者的适当电击风险,但不能预测死亡率。
Europace. 2017 Oct 1;19(10):1689-1694. doi: 10.1093/europace/euw323.
3
Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.导致冠心病或非缺血性扩张型心肌病患者 ICD 干预的致室性心律失常的相关因素。
Kardiol Pol. 2012;70(12):1264-75.
4
[Efficacy of alcohol septal ablation in mildly symptomatic or severely symptomatic patients with hypertrophic obstructive cardiomyopathy].[酒精间隔消融术治疗轻度症状或重度症状肥厚型梗阻性心肌病患者的疗效]
Zhonghua Xin Xue Guan Bing Za Zhi. 2023 May 24;51(5):513-520. doi: 10.3760/cma.j.cn112148-20220613-00470.
5
Cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy: single center implant data extracted from the Swedish pacemaker and ICD registry.肥厚型心肌病患者的心脏植入式电子设备:从瑞典起搏器和 ICD 登记处提取的单中心植入数据。
Scand Cardiovasc J. 2020 Aug;54(4):239-247. doi: 10.1080/14017431.2020.1727000. Epub 2020 Feb 13.
6
Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy.终末期肥厚型心肌病的影响因素及预后因素
ESC Heart Fail. 2024 Dec;11(6):4028-4037. doi: 10.1002/ehf2.15010. Epub 2024 Aug 2.
7
Prognostic impact of newly detected atrial fibrillation in patients with hypertrophic cardiomyopathy following cardiac implantable electronic device implantation.心脏植入式电子设备植入后肥厚型心肌病患者中新发现的心房颤动对预后的影响。
Heart Vessels. 2021 May;36(5):667-674. doi: 10.1007/s00380-020-01728-4. Epub 2020 Nov 21.
8
Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.肥厚型心肌病患者接受植入式心脏复律除颤器一级预防后左室内压力梯度。
BMC Cardiovasc Disord. 2021 Feb 19;21(1):106. doi: 10.1186/s12872-021-01910-0.
9
Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy.经胸多普勒超声心动图冠状动脉血流储备在不对称性肥厚型心肌病患者中的预测价值。
J Am Heart Assoc. 2021 Oct 19;10(20):e021936. doi: 10.1161/JAHA.120.021936. Epub 2021 Oct 12.
10
Echocardiographic variables predictive of appropriate therapies for ventricular tachyarrhythmia in patients undergoing combined cardiac resynchronization therapy.
Rev Port Cardiol. 2010 Jun;29(6):1009-19.

本文引用的文献

1
Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.肥厚型心肌病 NHLBI 登记处的不同亚组。
J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345. doi: 10.1016/j.jacc.2019.08.1057.
2
Pacing-induced cardiomyopathy in chronic right ventricular apical pacing: a midterm follow-up study.慢性右心室心尖部起搏致起搏诱导性心肌病:一项中期随访研究。
Eur J Med Res. 2019 Jul 22;24(1):23. doi: 10.1186/s40001-019-0386-5.
3
Predictors of long-term outcome after septal myectomy in symptomatic hypertrophic obstructive cardiomyopathy patients with previous alcohol septal ablation and residual obstruction.
有症状的肥厚性梗阻性心肌病患者先前接受酒精室间隔消融术及存在残余梗阻后行室间隔心肌切除术的长期预后预测因素。
J Card Surg. 2019 Jul;34(7):533-540. doi: 10.1111/jocs.14072. Epub 2019 May 21.
4
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2018年美国心脏病学会/美国心脏协会/心律学会关于心动过缓和心脏传导延迟患者评估与管理的指南:美国心脏病学会/美国心脏协会临床实践指南工作组及心律学会的报告
Circulation. 2019 Aug 20;140(8):e382-e482. doi: 10.1161/CIR.0000000000000628. Epub 2018 Nov 6.
5
Association of selected factors with long-term prognosis and mortality after dual-chamber pacemaker implant.选择因素与双腔起搏器植入后长期预后和死亡率的关系。
Cardiol J. 2019;26(6):717-726. doi: 10.5603/CJ.a2018.0093. Epub 2018 Aug 29.
6
Clinical Course and Management of Hypertrophic Cardiomyopathy.肥厚型心肌病的临床病程与管理
N Engl J Med. 2018 Aug 16;379(7):655-668. doi: 10.1056/NEJMra1710575.
7
The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses.抑郁与全因和死因特异性死亡率的关联:系统评价和荟萃分析的伞式综述。
BMC Med. 2018 Jul 20;16(1):112. doi: 10.1186/s12916-018-1101-z.
8
Hypertrophic Cardiomyopathy-Past, Present and Future.肥厚型心肌病——过去、现在与未来
J Clin Med. 2017 Dec 12;6(12):118. doi: 10.3390/jcm6120118.
9
Short atrioventricular delay pacing therapy in young and old patients with hypertrophic obstructive cardiomyopathy: good long-term results and a low need for reinterventions.短房室延迟起搏治疗肥厚型梗阻性心肌病的年轻和老年患者:良好的长期结果和较低的再干预需求。
Europace. 2018 Oct 1;20(10):1683-1691. doi: 10.1093/europace/eux331.
10
Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions.肥厚型梗阻性心肌病的起搏治疗:更新与未来方向。
Europace. 2018 Jun 1;20(6):908-920. doi: 10.1093/europace/eux131.